xtandi
astellas pharma europe b.v. - enzalutamid - nowotwory stercza - terapia endokrynologiczna - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
zoladex 3,6 mg implant podskórny
astrazeneca ab - goserelini acetas - implant podskórny - 3,6 mg
zoladex la 10,8 mg implant podskórny
astrazeneca ab - goserelini acetas - implant podskórny - 10,8 mg
anastralan 1 mg tabletki powlekane
pharmaswiss ceska republika s.r.o. - anastrozolum - tabletki powlekane - 1 mg
mamostrol 1 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - anastrozolum - tabletki powlekane - 1 mg
ansyn 1 mg tabletki powlekane
actavis group ptc ehf. - anastrozolum - tabletki powlekane - 1 mg
anastrin 1 mg tabletki powlekane
adamed sp. z o.o. - anastrozolum - tabletki powlekane - 1 mg
anastrozol bluefish 1 mg tabletki powlekane
bluefish pharmaceuticals ab - anastrozolum - tabletki powlekane - 1 mg
axastrol 1 mg tabletki powlekane
grindex as - anastrozolum - tabletki powlekane - 1 mg
reseligo 3,6 mg implant w ampułko-strzykawce
zentiva, k.s. - goserelini acetas - implant w ampułko-strzykawce - 3,6 mg